

Docket No. 220243US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#2

IN RE APPLICATION OF: Stephen ARKINSTALL, et al.
SERIAL NO: New US PCT application based on PCT/IB00/01381
FILED: Herewith
FOR: PHARMACEUTICALLY ACTIVE SULFONYL HYDRAZIDE DERIVATIVES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:
Applicant(s) wish to disclose the following information.

REFERENCES

The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.

A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.

A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBOLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Surinder Sachar

Norman F. Oblon

Registration No. 24,618



22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 10/01)

Surinder Sachar
Registration No. 34,423

Form PTO 1449 (Modified) LIST OF REFERENCES CITED BY APPLICANT		ATTY DOCKET NO. 220243US0PCT		SERIAL NO. New US PCT application based on PCT/IB00/01381	
		APPLICANT Stephen ARKINSTALL, et al.			
		FILING DATE Herewith		GROUP	
		U.S. PATENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS SUB CLASS FILING DATE IF APPROPRIATE
	AA				
	AB				
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				
	AL				
	AM				
	AN				
FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
	AO	98 49188	11/05/98	WO	
	AP	0 330 065	08/30/89	EP	
	AQ				
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)					
	AR	R. Raja REDDY et al.: "New hypoglycemic agents--Part XVI: synthesis and evaluation of N3-aryl-N1-'4'-(3, 4-dihydro-3-oxo-2H-1, 4-benzoxazin-2-yl) acetic acid hydrazidosulfonylphenyl ureas/thioureas" INDIAN JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 7, no. 3, pages 185-188 1998			
	AS	Xie XIAOLING et al.: "Crystal structure of JNK3: a kinase implicated in neuronal apoptosis" STRUCTURE, 6 (8), pages 983-991 1998			
	AT	Derek D. YANG et al.: "Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene" NATURE, 389 (6653), pages 865-870 1997			
	AU	Derek D. YANG et al.: "Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2" IMMUNITY, 9, pages 575-585 1998			
	AV	Kanaga SABAPATHY et al.: "JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development" CURRENT BIOLOGY, 3, pages 116-125 1999			
	AW	Yoshihiro KUMAGAE et al.: "Human c-Jun N-terminal kinase expression and activation in the nervous system" BRAIN RES. MOL. BRAIN RES., 67 (1), pages 10-17 1999		<input type="checkbox"/> Additional References sheet(s) attached	
Examiner			Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					